424 related articles for article (PubMed ID: 25281710)
1. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
[TBL] [Abstract][Full Text] [Related]
2. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
Yang JC; Kang JH; Mok T; Ahn MJ; Srimuninnimit V; Lin CC; Kim DW; Tsai CM; Barraclough H; Altug S; Orlando M; Park K
Eur J Cancer; 2014 Sep; 50(13):2219-30. PubMed ID: 24953333
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J
Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
Kim YS; Cho EK; Woo HS; Hong J; Ahn HK; Park I; Sym SJ; Kyung SY; Kang SM; Park JW; Jeong SH; Park J; Lee JH; Shin DB
Cancer Res Treat; 2016 Jan; 48(1):80-7. PubMed ID: 25761488
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
10. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study.
Yang JC; Srimuninnimit V; Ahn MJ; Lin CC; Kim SW; Tsai CM; Mok T; Orlando M; Puri T; Wang X; Park K
J Thorac Oncol; 2016 Mar; 11(3):370-9. PubMed ID: 26725183
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
12. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
[TBL] [Abstract][Full Text] [Related]
13. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
Boye M; Wang X; Srimuninnimit V; Kang JH; Tsai CM; Orlando M; Puri T; Kim JS; Rajan N; Yang JC
Clin Lung Cancer; 2016 Mar; 17(2):150-60. PubMed ID: 26809984
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Ahn MJ; Yang JC; Liang J; Kang JH; Xiu Q; Chen YM; Blair JM; Peng G; Linn C; Orlando M
Lung Cancer; 2012 Aug; 77(2):346-52. PubMed ID: 22534669
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
[TBL] [Abstract][Full Text] [Related]
17. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
18. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Hong J; Kyung SY; Lee SP; Park JW; Jung SH; Lee JI; Park SH; Sym SJ; Park J; Cho EK; Shin DB; Lee JH
Korean J Intern Med; 2010 Sep; 25(3):294-300. PubMed ID: 20830227
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
